Compare ABLV & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABLV | FEMY |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 37.2M |
| IPO Year | N/A | 2021 |
| Metric | ABLV | FEMY |
|---|---|---|
| Price | $0.74 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 19.6K | ★ 1.2M |
| Earning Date | 09-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $114,319,869.00 | $2,061,502.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | N/A | $147.19 |
| P/E Ratio | $15.66 | ★ N/A |
| Revenue Growth | N/A | ★ 63.53 |
| 52 Week Low | $0.59 | $0.31 |
| 52 Week High | $1.77 | $1.80 |
| Indicator | ABLV | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 39.88 |
| Support Level | $0.65 | $0.60 |
| Resistance Level | $0.77 | $0.73 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 64.29 | 10.56 |
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.